US · HSDT
Solana Company
- Sector
- Healthcare · Medical - Devices
- Headquarters
- Newtown, PA 18940
- Website
- solana.com
Price · as of 2024-12-31
$2.12
Market cap 75.36M
Valuation summary
Four models, one snapshot. Upside is target ÷ current − 1.
| Valuation method | Value, $ | Upside, % |
|---|---|---|
| Artificial Intelligence(AI) | $143.23 | +6,656.13% |
| Intrinsic Value(DCF) | $247.42 | +11,570.75% |
| Graham-Dodd Method(GD) | — | — |
| Graham Formula(GF) | $44.35 | +1,991.93% |
Valuation history
Annual price (USD per share) overlaid with each model's fair value. Y-axis is log scale.
| Year | Price | AI | DCF | Graham-Dodd | Graham Formula |
|---|---|---|---|---|---|
| 2010 | |||||
| 2011 | |||||
| 2012 | |||||
| 2013 | |||||
| 2014 | |||||
| 2015 | $15,093,750.00 | ||||
| 2016 | $5,939,062.50 | ||||
| 2017 | $15,789,375.00 | ||||
| 2018 | $8,216,250.00 | ||||
| 2019 | $972,562.50 | $389,636.50 | $0.00 | $0.00 | $0.00 |
| 2020 | $531,750.00 | $223,501.79 | $0.00 | $0.00 | $13,343.57 |
| 2021 | $115,125.00 | $46,083.82 | $0.00 | $0.00 | $2,206.12 |
| 2022 | $9,112.50 | $3,655.07 | $0.00 | $0.00 | $0.00 |
| 2023 | $4,440.00 | $2,051.78 | $0.00 | $0.00 | $67.54 |
| 2024 | $337.50 | $143.23 | $0.00 | $0.00 | $44.35 |
AI valuation
Our deep-learning model estimates Solana Company's (HSDT) per-share fair value from quarterly fundamentals, sector trend, and historical valuation patterns.
- AI fair value
- $143.23
- Current price
- $2.12
- AI upside
- +6,656.13%
Methodology and confidence bands appear in the dedicated valuation theory section. The AI score is an estimate, not a recommendation.
Intrinsic value (DCF)
Open DCF calculatorThree textbook valuation models, recomputed daily from the latest financial statements. The DCF uses our Chepakovich model. Graham-Dodd and Graham Formula are conservative reference points.
DCF
$247.42
+11,570.75% upside
Graham-Dodd
—
— upside
Graham Formula
$44.35
+1,991.93% upside
Peer comparison
Same-industry comparables, ranked by market cap.
| Basic Info | Model Valuation | Core Valuation | Profitability | Leverage & Liquidity | Growth | Cash Flow | Dividends | Enterprise Value | Risk | ||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Ticker | Company Name | Price | Market Cap | AI Upside | DCF Upside | GD Upside | GF Upside | P/E | P/B | P/S | EV/EBITDA | PEG | P/TBV | Gross Margin | Operating Margin | Net Margin | ROE | ROIC | ROA | Debt/Equity | Interest Coverage | Current Ratio | Quick Ratio | Net Debt/EBITDA | EPS Growth | Sales Growth | FCF Growth | FCF Yield | Op Cash Flow Ratio | Cash ROIC | Dividend Yield | Dividend Payout | Shareholder Yield | EV/EBIT | EV/FCF | EV/Sales | Altman Z-Score |
| HSDT | Solana Company | $2.12 | 75.36M | +6,656% | +11,571% | — | +1,992% | -77.89 | 863.60 | 1758.75 | -66.18 | — | 863.60 | -11.92% | -2673.65% | -2258.08% | -688.88% | 995.92% | -209.04% | 0.01 | -817.82 | 1.58 | 0.80 | 0.08 | -4052.00% | -1925.00% | 575.00% | -1.21% | -5.10 | 791.26% | 0.00% | 0.00% | 0.00% | -65.70 | -82.70 | 1756.68 | 140.75 |
| INGN | Inogen, Inc. | $6.10 | 165.61M | +2,817% | -47% | -59% | — | -7.38 | 0.87 | 0.48 | -24.21 | — | 1.11 | 47.58% | -8.66% | -6.52% | -12.43% | -34.66% | -7.65% | 0.09 | — | 3.12 | 2.49 | 31.71 | -4408.00% | 386.00% | 9321.00% | -12.86% | -0.18 | -25.47% | 0.00% | 0.00% | 0.00% | -2.18 | -3.05 | 0.19 | 1.50 |
| NNOX | Nano-X Imaging Ltd. | $2.37 | 151.12M | +990% | +2% | — | — | -6.62 | 1.87 | 31.38 | -6.41 | — | 2.97 | -94.03% | -502.93% | -474.31% | -27.83% | -46.04% | -24.97% | 0.04 | — | 5.63 | 5.37 | 0.71 | -1574.00% | 1391.00% | -1813.00% | -11.12% | -2.62 | -32.15% | 0.00% | 0.00% | 0.00% | -5.08 | -7.32 | 25.55 | 7.21 |
| OM | Outset Medical, Inc. | $3.49 | 63.91M | +1,299% | -32% | — | — | — | 0.43 | 0.45 | 0.16 | — | 0.43 | 39.13% | -55.84% | -68.34% | 0.00% | -100.69% | 0.00% | 0.82 | -4.78 | 6.67 | 5.24 | -1.11 | -8547.00% | 509.00% | -5980.00% | -86.78% | -1.23 | -71.12% | 0.00% | — | 15.34% | 0.15 | 0.21 | -0.08 | -5.38 |
| PROF | Profound Medical Corp. | $7.61 | 229.84M | +279% | -61% | — | — | -6.11 | 2.81 | 16.71 | -4.69 | — | 2.82 | 65.89% | -309.57% | -260.45% | -60.70% | -267.75% | -48.72% | 0.08 | — | 10.52 | 9.44 | 1.95 | -2074.00% | 4123.00% | 373.00% | -13.80% | -3.57 | -199.52% | 0.00% | 0.00% | 18.51% | -3.82 | -5.12 | 11.81 | 5.24 |
| QTRX | Quanterix Corporation | $6.55 | 305.96M | +237% | -22% | -45% | — | -7.37 | 0.86 | 2.10 | -0.73 | -45.26 | 0.87 | 59.89% | -38.85% | -28.45% | -11.33% | -70.92% | -9.23% | 0.11 | — | 8.66 | 7.65 | 0.44 | 1628.00% | 1180.00% | 6982.00% | -13.57% | -0.84 | -51.94% | 0.00% | 0.00% | 0.00% | -0.61 | -0.83 | 0.24 | 1.46 |
| SNWV | SANUWAVE Health, Inc. | $24.33 | 208.62M | +2,106% | +2,696% | — | — | -4.13 | -10.18 | 3.97 | -8.74 | — | -5.46 | 75.23% | 16.60% | -96.13% | 112.25% | -90.44% | -119.43% | -2.00 | 0.40 | 0.43 | 0.32 | -0.92 | -4233.00% | 5999.00% | -14330.00% | 1.52% | 0.06 | -32.81% | 0.00% | 0.00% | 10.35% | 26.71 | 73.63 | 4.43 | -9.15 |
| TLSI | TriSalus Life Sciences, I… | $5.06 | 167.17M | +547% | +1,763% | — | — | -4.73 | -5.49 | 4.83 | -4.35 | — | -5.49 | 86.06% | -122.88% | -112.92% | 113.47% | 150.57% | -123.72% | -0.91 | -11.70 | 2.02 | 1.33 | -0.42 | -4395.00% | 5899.00% | -1950.00% | -29.00% | -3.99 | 171.48% | 0.00% | 0.00% | 0.00% | -4.35 | -3.82 | 5.34 | -17.85 |
About Solana Company
Solana Co. is a neurotech company in the medical device industry that focuses on neurological wellness. The firm develops, licenses and acquires non-invasive platform technologies that amplify the brain’s ability to heal itself and reduce symptoms of neurological disease or trauma. It engages in the development of the investigational portable neuromodulation stimulator, that delivers neurostimulation via the tongue which has been shown in clinical studies to enhance the effectiveness of physical exercises in people with neurological symptoms from disease or trauma such as mild-to-moderate traumatic brain injury. The company was founded on March 13, 2014 and is headquartered in Newtown, PA.
- CEO
- Dane Carl Andreeff
- Employees
- 21
- Beta
- 1.05
Disclaimer: Information on this page is provided for educational purposes only and does not constitute investment advice. Upside computed as ($247.42 ÷ $2.12) − 1 = +11,570.75% (DCF, example).